Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic
- PMID: 32475830
- DOI: 10.1136/annrheumdis-2020-217935
Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic
Keywords: autoimmune diseases; epidemiology; health services research.
Conflict of interest statement
Competing interests: GEF: has received speaker honoraria from Janssen, travelling grants from AbbVie and MSD. MGT: has received consultant fees and unrestricted grants from AbbVie, MSD, Novartis, Pfizer, GSK and UCB deposited to the Special Account for Research Funding (ELKE) of the National and Kapodistrian University of Athens Medical School. PPS: has received consultant fees and unrestricted grants from AbbVie, Pfizer, MSD, Roche, UCB, GSK and Novartis deposited to the Special Account for Research Funding (ELKE) of the National and Kapodistrian University of Athens Medical School.
Comment in
-
Response to: 'Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic' by Fragoulis et al.Ann Rheum Dis. 2021 Apr;80(4):e61. doi: 10.1136/annrheumdis-2020-217987. Epub 2020 May 31. Ann Rheum Dis. 2021. PMID: 32475833 No abstract available.
Comment on
-
Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic.Ann Rheum Dis. 2020 Jun;79(6):840-842. doi: 10.1136/annrheumdis-2020-217628. Epub 2020 Apr 28. Ann Rheum Dis. 2020. PMID: 32345619 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
